The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy

A randomized, dose-ranging, placebo-controlled clinical trial

Irinel Popescu, Phillip R. Fleshner, John C. Pezzullo, Philippa A. Charlton, Gordana Kosutic, Anthony J. Senagore

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in postoperative ileus management. Methods: Adults undergoing open partial colectomy were adaptively randomized to receive 20, 40, 80, 160, 320, 480 or 600 μg/kg TZP-101 (n = 168) or the placebo (n = 68) by 30-minute IV infusion within 1 hour of surgical closure and then daily for up to 7 days. The primary efficacy end point was the time to first bowel movement. Secondary end points included the percentage of patients with return of gastrointestinal function within 72 hours, and the time to readiness for discharge. Results: TZP-101 accelerated the time to first bowel movement in all groups, with Cox proportional hazard ratios of 1.57 (P = .056) for the low-efficacious dose (80 μg/kg) and 1.67 (P = .03) for the most efficacious dose (480μg/kg). Using Kaplan-Meier analysis, the median time to first bowel movement was reduced in all TZP-101 groups by 10 to 22 hours vs. the placebo. A greater number of patients who received TZP-101 achieved recovery (P ≤ .001) by 72 hours postsurgery compared with the placebo. The median time to readiness for hospital discharge was significantly accelerated by 20.4 hours at the 480 μg/kg TZP-101 dose compared with the placebo (hazard ratio = 1.69; P = .03). The most common treatment-emergent adverse events were nausea and vomiting, which were reduced in the TZP-101 group compared with the placebo group. Conclusion: In patients undergoing major abdominal surgery, the first-in-class ghrelin agonist TZP-101 was well-tolerated and accelerated recovery of the upper and lower gastrointestinal tract, with a large proportion of subjects recovering within 72 hours compared with the placebo.

Original languageEnglish (US)
Pages (from-to)126-134
Number of pages9
JournalDiseases of the Colon and Rectum
Volume53
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Ghrelin
Colectomy
Ileus
Controlled Clinical Trials
Placebos
Lower Gastrointestinal Tract
ulimorelin
Upper Gastrointestinal Tract
Kaplan-Meier Estimate
Nausea
Vomiting
Safety

Keywords

  • Abdominal surgery
  • Gastrointestinal
  • Ghrelin agonist
  • Ileus
  • Prokinetic

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy : A randomized, dose-ranging, placebo-controlled clinical trial. / Popescu, Irinel; Fleshner, Phillip R.; Pezzullo, John C.; Charlton, Philippa A.; Kosutic, Gordana; Senagore, Anthony J.

In: Diseases of the Colon and Rectum, Vol. 53, No. 2, 02.2010, p. 126-134.

Research output: Contribution to journalArticle

Popescu, Irinel ; Fleshner, Phillip R. ; Pezzullo, John C. ; Charlton, Philippa A. ; Kosutic, Gordana ; Senagore, Anthony J. / The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy : A randomized, dose-ranging, placebo-controlled clinical trial. In: Diseases of the Colon and Rectum. 2010 ; Vol. 53, No. 2. pp. 126-134.
@article{d59b9fd008514bfc9951c6c5575fbf9e,
title = "The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: A randomized, dose-ranging, placebo-controlled clinical trial",
abstract = "Purpose: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in postoperative ileus management. Methods: Adults undergoing open partial colectomy were adaptively randomized to receive 20, 40, 80, 160, 320, 480 or 600 μg/kg TZP-101 (n = 168) or the placebo (n = 68) by 30-minute IV infusion within 1 hour of surgical closure and then daily for up to 7 days. The primary efficacy end point was the time to first bowel movement. Secondary end points included the percentage of patients with return of gastrointestinal function within 72 hours, and the time to readiness for discharge. Results: TZP-101 accelerated the time to first bowel movement in all groups, with Cox proportional hazard ratios of 1.57 (P = .056) for the low-efficacious dose (80 μg/kg) and 1.67 (P = .03) for the most efficacious dose (480μg/kg). Using Kaplan-Meier analysis, the median time to first bowel movement was reduced in all TZP-101 groups by 10 to 22 hours vs. the placebo. A greater number of patients who received TZP-101 achieved recovery (P ≤ .001) by 72 hours postsurgery compared with the placebo. The median time to readiness for hospital discharge was significantly accelerated by 20.4 hours at the 480 μg/kg TZP-101 dose compared with the placebo (hazard ratio = 1.69; P = .03). The most common treatment-emergent adverse events were nausea and vomiting, which were reduced in the TZP-101 group compared with the placebo group. Conclusion: In patients undergoing major abdominal surgery, the first-in-class ghrelin agonist TZP-101 was well-tolerated and accelerated recovery of the upper and lower gastrointestinal tract, with a large proportion of subjects recovering within 72 hours compared with the placebo.",
keywords = "Abdominal surgery, Gastrointestinal, Ghrelin agonist, Ileus, Prokinetic",
author = "Irinel Popescu and Fleshner, {Phillip R.} and Pezzullo, {John C.} and Charlton, {Philippa A.} and Gordana Kosutic and Senagore, {Anthony J.}",
year = "2010",
month = "2",
doi = "10.1007/DCR.0b013e3181b54166",
language = "English (US)",
volume = "53",
pages = "126--134",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy

T2 - A randomized, dose-ranging, placebo-controlled clinical trial

AU - Popescu, Irinel

AU - Fleshner, Phillip R.

AU - Pezzullo, John C.

AU - Charlton, Philippa A.

AU - Kosutic, Gordana

AU - Senagore, Anthony J.

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in postoperative ileus management. Methods: Adults undergoing open partial colectomy were adaptively randomized to receive 20, 40, 80, 160, 320, 480 or 600 μg/kg TZP-101 (n = 168) or the placebo (n = 68) by 30-minute IV infusion within 1 hour of surgical closure and then daily for up to 7 days. The primary efficacy end point was the time to first bowel movement. Secondary end points included the percentage of patients with return of gastrointestinal function within 72 hours, and the time to readiness for discharge. Results: TZP-101 accelerated the time to first bowel movement in all groups, with Cox proportional hazard ratios of 1.57 (P = .056) for the low-efficacious dose (80 μg/kg) and 1.67 (P = .03) for the most efficacious dose (480μg/kg). Using Kaplan-Meier analysis, the median time to first bowel movement was reduced in all TZP-101 groups by 10 to 22 hours vs. the placebo. A greater number of patients who received TZP-101 achieved recovery (P ≤ .001) by 72 hours postsurgery compared with the placebo. The median time to readiness for hospital discharge was significantly accelerated by 20.4 hours at the 480 μg/kg TZP-101 dose compared with the placebo (hazard ratio = 1.69; P = .03). The most common treatment-emergent adverse events were nausea and vomiting, which were reduced in the TZP-101 group compared with the placebo group. Conclusion: In patients undergoing major abdominal surgery, the first-in-class ghrelin agonist TZP-101 was well-tolerated and accelerated recovery of the upper and lower gastrointestinal tract, with a large proportion of subjects recovering within 72 hours compared with the placebo.

AB - Purpose: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in postoperative ileus management. Methods: Adults undergoing open partial colectomy were adaptively randomized to receive 20, 40, 80, 160, 320, 480 or 600 μg/kg TZP-101 (n = 168) or the placebo (n = 68) by 30-minute IV infusion within 1 hour of surgical closure and then daily for up to 7 days. The primary efficacy end point was the time to first bowel movement. Secondary end points included the percentage of patients with return of gastrointestinal function within 72 hours, and the time to readiness for discharge. Results: TZP-101 accelerated the time to first bowel movement in all groups, with Cox proportional hazard ratios of 1.57 (P = .056) for the low-efficacious dose (80 μg/kg) and 1.67 (P = .03) for the most efficacious dose (480μg/kg). Using Kaplan-Meier analysis, the median time to first bowel movement was reduced in all TZP-101 groups by 10 to 22 hours vs. the placebo. A greater number of patients who received TZP-101 achieved recovery (P ≤ .001) by 72 hours postsurgery compared with the placebo. The median time to readiness for hospital discharge was significantly accelerated by 20.4 hours at the 480 μg/kg TZP-101 dose compared with the placebo (hazard ratio = 1.69; P = .03). The most common treatment-emergent adverse events were nausea and vomiting, which were reduced in the TZP-101 group compared with the placebo group. Conclusion: In patients undergoing major abdominal surgery, the first-in-class ghrelin agonist TZP-101 was well-tolerated and accelerated recovery of the upper and lower gastrointestinal tract, with a large proportion of subjects recovering within 72 hours compared with the placebo.

KW - Abdominal surgery

KW - Gastrointestinal

KW - Ghrelin agonist

KW - Ileus

KW - Prokinetic

UR - http://www.scopus.com/inward/record.url?scp=77449137453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449137453&partnerID=8YFLogxK

U2 - 10.1007/DCR.0b013e3181b54166

DO - 10.1007/DCR.0b013e3181b54166

M3 - Article

VL - 53

SP - 126

EP - 134

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 2

ER -